ACADIA Pharmaceuticals (ACAD) Gets a Hold from Bank of America Securities
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed yesterday at $21.77.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Ahmad is an analyst with an average return of -1.3% and a 49.49% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and PTC Therapeutics.
In addition to Bank of America Securities, ACADIA Pharmaceuticals also received a Hold from Morgan Stanley's Sean Laaman in a report issued on May 20. However, on the same day, Deutsche Bank upgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) to a Buy.
ACAD market cap is currently $3.59B and has a P/E ratio of 16.00.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
21 minutes ago
- Business Insider
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
In a report released today, Edward Woo from Ascendiant maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), with a price target of $7.50. The company's shares opened today at $0.87. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Woo covers the Healthcare sector, focusing on stocks such as GRI Bio, Envoy Medical, and Cingulate Inc. According to TipRanks, Woo has an average return of -8.2% and a 34.36% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atossa Therapeutics with a $5.56 average price target, a 539.08% upside from current levels. In a report released today, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $4.00 price target.
Business Insider
21 minutes ago
- Business Insider
Wolfe Research Sticks to Its Buy Rating for Samsara (IOT)
Wolfe Research analyst Alex Zukin maintained a Buy rating on Samsara (IOT – Research Report) today and set a price target of $45.00. The company's shares opened today at $42.75. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Zukin is a 5-star analyst with an average return of 19.1% and a 62.55% success rate. Zukin covers the Technology sector, focusing on stocks such as Salesforce, Okta, and Zscaler. In addition to Wolfe Research, Samsara also received a Buy from William Blair's Dylan Becker in a report issued today. However, on the same day, Truist Financial reiterated a Hold rating on Samsara (NYSE: IOT). The company has a one-year high of $61.90 and a one-year low of $27.14. Currently, Samsara has an average volume of 4.44M. Based on the recent corporate insider activity of 243 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IOT in relation to earlier this year. Most recently, in March 2025, James Andrew Munk, the CAO of IOT sold 9,369.00 shares for a total of $361,542.21.
Business Insider
21 minutes ago
- Business Insider
Top U.S. Automaker Rare Earth Suppliers Receive Export Licenses from China
Last week, President Trump accused China of violating its preliminary trade deal reached with the U.S. These violations included the continued restriction of rare earth element exports, which are critical in the development of semiconductors, cars, and planes. Now, China has responded in favor of the U.S. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter China has provided temporary rare earth export licenses to suppliers of three top U.S. automaker brands, General Motors (GM), Ford (F), and Stellantis (STLA), per Reuters. This comes after Beijing imposed rare earth export restrictions in April as a response to Trump's tariffs, although the restrictions didn't apply just to the U.S. Automakers around the world had previously warned of supply chain disruptions if China continued to restrict the elements. China Eases Rare Earth Exports to Top U.S. Automakers The export licenses will be in effect for six months, with the timeline possibly set in order to respond to U.S.-China trade developments. Reuters ' sources didn't mention the quantity or exact rare earths covered through the export licenses. China holds a near-monopoly on rare earths and produces about 90% of them across the globe.
